Open AccessReal-world genetic testing patterns in metastatic castration-resistant prostate cancer
Author(s) -
Neal D. Shore,
Raluca IonescuIttu,
Lingfeng Yang,
François Laliberté,
Malena Mahendran,
Dominique Lejeune,
Louise Yu,
Joseph E. Burgents,
Mei Sheng Duh,
Sameer R. Ghate
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0153
Subject(s) - medicine , genetic testing , prostate cancer , fanca , oncology , cancer , palb2 , referral , mutation , dna repair , gene , family medicine , germline mutation , genetics , fanconi anemia , biology
Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.